Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
BlueRock Therapeutics

BlueRock Therapeutics

A biotechnology company developing engineered cell therapies for treating diseases in neurology, cardiology and autoimmunity.

BlueRock Therapeutics is a biotechnology company headquartered in New York City, New York that was founded by Lorenz Studer, Gordon Keller, Michael Laflamme, and Viviane Tabar.

Products

BlueRock is using their Cell plus Gene platform to produce cell therapies for replacement of damaged or degenerated tissue. BlueRock’s neurology pipeline focuses on Parkinson’s Disease and engineering microglia for other neurological disorders. Their cardiology pipeline includes cell therapy for heart failure using cardiomyocytes. For autoimmune diseases, the company is designing macrophage cell therapies. BlueRock is using ex vivo engineering to enable cells to produce enzymes, antibodies and other proteins with therapeutic benefit.

Cell therapy candidates are based on induced pluripotent stem (IPS) cell technology. The company’s approach is based on iPSC intellectual property invented by Shinya Yamanaka of Kyoto University in Japan and licensed from iPS Academia Japan, which manages iPSC IP.

Partnerships
Memorial Sloan Kettering Cancer Center and the Centre for Commercializing of Regenerative Medicine (CCRM)

BlueRock has partnerships with Memorial Sloan Kettering Cancer Center and Toronto-based Centre for Commercialization of Regenerative Medicine (CCRM).

The McEwen Stem Cell Institute

In December 2018, BlueRock partnered with The McEwen Stem Cell Institute at the University Health Network (UHN) in Toronto’s MaRS Discovery District. A new pilot Good Manufacturing Practices (GMP) facility will open in 2019.

Funding
Series A

On December 12, 2016 BlueRock Therapeutics completed their series A funding round with $225 million in funding from Versant Ventures and Bayer AG.

Timeline

August 8, 2019
Bayer buys BlueRock in $600 million bet on stem cell therapies

DE) is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up investment in a promising new medical area to revive its drug development pipeline. Having established BlueRock as part of a 2016 joint venture with Versant Ventures, Bayer will acquire the remaining 59.2% stake for about $240 million upfront and an additional $360 million depending on certain development achievements, it said on Thursday.

December 2016
Versant Ventures and Bayer provided US$225-million in financing to establish BlueRock Therapeutics
December 2016
BlueRock Therapeutics raises a $225,000,000 series A round from Bayer and Versant Ventures.
2016
BlueRock Therapeutics was founded by Gordon Keller.

Funding Rounds

Patents

Further Resources

Title
Author
Link
Type
Date

$225M BlueRock Therapeutics "monster" a magnet for Canada's biotech sector

Financial Post

News

BlueRock Therapeutics Strengthens Collaboration with the McEwen Stem Cell Institute

BlueRock Therapeutics

Web

BlueRock Therapeutics: A regenerative medicine game-changer

Invest Ontario

Web

What You Need to Know About BlueRock Therapeutics

Mark Terry

Web

News

Title
Author
Date
Publisher
Description
Kyle LaHucik
July 26, 2021
FierceBiotech
Bayer-owned subsidiary BlueRock Therapeutics is promoting Chief Scientific Officer Seth Ettenberg, Ph.D., to president and CEO, as Emile Nuwaysir, Ph.D., will transition to board chair on August 1.
Amirah Al Idrus
July 20, 2021
FierceBiotech
Six weeks after landing in the clinic, Bayer's stem cell therapy for Parkinson's disease is getting into the fast lane. The German pharma picked up the treatment, DA01, by buying Versant Ventures out of their regenerative medicine joint venture BlueRock Therapeutics in a deal worth about $1 billion.
Alex Keown
June 8, 2021
BioSpace
Bayer is taking multiple shots at Parkinson's disease with BlueRock dosing its first patient in a Phase I stem cell study, and AskBio is assessing a gene therapy treatment for the disease.
Kate Goodwin
May 27, 2021
BioSpace
Determined to take its next-generation engineered cell therapies to the next level, BlueRock teams up with Senti Biosciences with futuristic medicines in mind.
BlueRock Therapeutics
January 7, 2021
www.prnewswire.com:443
/PRNewswire/ -- BlueRock Therapeutics, a preclinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, in collaboration with Memorial...
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.